Trial Profile
A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Intravenous Infusion of CAP-1002 in Patients With COVID-19 (INSPIRE)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Apr 2022
Price :
$35
*
At a glance
- Drugs CAP-1002 (Primary)
- Indications COVID 2019 infections; SARS-CoV-2 acute respiratory disease
- Focus Adverse reactions; Biomarker
- Acronyms INSPIRE
- Sponsors Capricor Therapeutics
- 29 Mar 2022 The primary outcomes were changed from Number of all-cause mortality cases (30 days), Efficacy of CAP-1002 on Cytokine, and Efficacy of CAP-1002 on Laboratory Biomarker to Safety of CAP-1002: Incidence of All-Cause Mortality (90 days), according to ClinicalTrials.gov.
- 29 Mar 2022 Status changed from active, no longer recruiting to completed.
- 28 Mar 2022 Results presented in a Capricor Therapeutics Media Release.